Study: Off-label use of antipsychotics growing in teens/young adults

A study published in JAMA Psychiatry reveals that 4.63 million antipsychotic prescriptions for written for teens and young adults in 2010. 

By Nicole Gray • July 12, 2015

What Glaxo's strategy guru thinks the future holds for HIV markets

David Redfern said that eventually the only improvement left to make in treating HIV will be finding a permanent cure.

By Nicole Gray • July 10, 2015

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Senior congressman joins chorus calling for heroin antidote price cut

Representative Elijah Cummings wrote to Governor Larry Hogan (R) to request that he cut a deal with Amphastar, which manufactures naloxone. 

By Nicole Gray • July 9, 2015

Pharma's newest adversaries on CME funding are... Hotel workers?

A 270,000-person strong hotel worker's union is fighting to end what it calls "out-of-control" CME payments by the pharma industry.

By Nicole Gray • July 7, 2015

Pharma flings accusations, dire predictions in wake of Greek financial crisis

Some say that a 'Grexit' would severely impact access to medications and their prices, while others are accusing pharma of twisting a crisis to shield its bottom line. 

By Nicole Gray • July 7, 2015

Big deal for biosims? Major French hospital group opts for Hospira's Remicade copy

Assistance Publique-Hôspitaux de Paris (AP-HP) is buying an infliximab biosimilar from the firm, which was acquired by Pfizer earlier this year, to treat its patients.    

By Nicole Gray • July 6, 2015

Drug makers warn EU over troubled Greece: Medicine supply 'may be in jeopardy'

The industry is warning that the Greek drug-supply chain may be severely disrupted if Greece leaves the Euro zone. 

By Nicole Gray • July 2, 2015

New study: Glaxo flu vax linked to increased narcolepsy risk

That's according to a study by Stanford researchers.

By Nicole Gray • July 2, 2015

Novo to halt Tresiba sales in Germany over pricing conflict

It's particularly striking given the size of the German market.

By Nicole Gray • July 2, 2015

'Innovation' is everywhere in biopharma—but what does that actually mean?

Innovation has many definitions. But it can’t exist without collaborative partnerships.

By Nicole Gray • July 2, 2015

Sanofi/MannKind might be facing a major flop with Afrezza inhaled insulin

Executives from the companies have been urging patience and promising better results down the line. But so far, the numbers are pretty bleak. 

By Nicole Gray • July 1, 2015

How Novartis' CEO wants to tackle an ever-aging world

Joe Jimenez spoke to McKinsey about his company's focus on serving the needs of an aging population.

By Nicole Gray • June 26, 2015

Bristol-Myers calls it quits on any new virology R&D programs

But the company's ongoing programs in virology will remain in place. 

By Nicole Gray • June 26, 2015

Report: It pays big to focus on diabetes drugs

According to a report from GlobalData, the diabetes medications market grew 5.1% in 2014.

By Nicole Gray • June 25, 2015

The early winners and losers in ASCO's highly anticipated cancer drug scorecard

ASCO's drug scorecard is designed to simplify therapeutic decision-making by comparing survival data for different regimens with costs and side effects. 

By Nicole Gray • June 24, 2015

Pay attention: Adults now main ADHD treatment target

That's according to the CEO of Shire. And he would know.

By Nicole Gray • June 23, 2015

More than 1,000 online drug sites under FDA scrutiny

FDA inspectors, along with other authorities, seized illegal drugs and medical devices received through post offices in Chicago, Miami, and New York. 

By Nicole Gray • June 19, 2015

Report: Global Rx drug sales to reach nearly $1 trillion by 2020

Assuming an annual compounded growth rate of 4.8% over the next five years, sales are expected to hit $987 billion in five years. 

By Nicole Gray • June 18, 2015

Biotech is booming—but is big pharma waning?

Between 2007 and 2013, biotech employment grew by 5%. But employment in pharma fell by about the same amount.

By Nicole Gray • June 16, 2015

How did Axovant raise $315M with one asset and no clinical data?

Avoxant went public based on the potential of a discarded Glaxo Alzheimer's drug—and little else. Is this the penultimate proof of a biotech bubble?

By Nicole Gray • June 15, 2015

LA county to finally distribute preventive Truvada

According to clinical data, preventive Truvada (tenofovir/emtricitabane), which is manufactured by Gilead, can reduce the risk of HIV infection by as much as 92% in at-risk men.

By Nicole Gray • June 12, 2015

How 21st Century Cures could change communications between biopharma, providers, & patients

Some are worried that expanding regulations around biopharma communications could lead to a "wild West" situation. But experts consider the proposed changes "modest."

By Nicole Gray • June 11, 2015

Pennsylvania's Melior wins a Parkinson's patent

The patent covers L-dopa-associated dyskinesia.

By Nicole Gray • June 11, 2015

PCSK9 anti-cholesterol drug prices: How much is too much?

Prime Therapeutics, a PBM, has warned that PCSK9 inhibitors could cost the healthcare system up to $23.3 billion per year.

By Nicole Gray • June 10, 2015

Report: Many heart attack patients neglect to take their meds afterwards

According to researchers from Duke University.

By Nicole Gray • June 4, 2015